Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 5 of 5 results for cefiderocol

  1. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections....

    Health technology evaluation
    Published
    17 August 2022
    View recommendations

    Sections for HTE2

  2. A new model for evaluating and purchasing antimicrobials in the UK

    the 2 products selected for the pilot: ceftazidime with avibactam and cefiderocol , in April 2022. This informed commercial discussions...

  3. Antimicrobial prescribing: cefiderocol (ES31)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Evidence summary
    Published
    2 December 2020

  4. NICE leads the way to develop a new approach to routinely value and pay for crucial antimicrobials

    James Love-Koh talks about the next steps for the 3-year project to develop a routine framework for evaluating and paying for new antimicrobials.

    News
    Last updated
    25 January 2024

  5. NICE reaches important milestone in the UK's efforts to tackle antimicrobial resistance.

    Two new antimicrobial drugs are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model.

    News
    Last updated
    15 January 2024